https://secure.businesswire.com/news/home/20250806119323/en/Prothena-Announces-that-Novo-Nordisk-Will-Advance-Coramitug-Formerly-PRX004-into-Phase-3-Development-for-ATTR-Amyloidosis-with-Cardiomyopathy
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3...
Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.